Skip to main content
. Author manuscript; available in PMC: 2014 Feb 14.
Published in final edited form as: J Med Ethics. 2013 Apr 4;40(2):139–142. doi: 10.1136/medethics-2013-101340

Table 3.

Health Care Providers’ Knowledge and Attitude about RTD

Knowledge and Attitude N %
Prior to survey, have you heard of RTD
 Yes 31 (34.1)
 No 60 (65.9)
 Missing/Unknown/No response 0 (0.0)
Rate your general knowledge of RTD
 None/limited 71 (78.0)
 Somewhat/knowledgeable 20 (22.0)
 Missing/Unknown/No response 0 (0.0)
Ethical or religious concerns about discussing RTD with a patient
 Yes 4 (4.4)
 No 87 (95.6)
 Missing/Unknown/No response 0 (0.0)
Comfortable discussing RTD with cancer patients
 Yes 36 (40.0)
 No 16 (17.8)
 Not sure 38 (42.2)
 Missing/Unknown/No response 1
Comfortable discussing RTD with a patient you are seeing for the first time
 Yes 8 (8.8)
 No 53 (58.2)
 Not sure 30 (32.9)
 Missing/Unknown/No response 0 (0.0)
Is your decision to discuss RTD with a patient influenced by your current knowledge of the topic
 Yes 51 (56.0)
 No 15 (16.5)
 Not sure 24 (26.4)
 Missing/Unknown/No response 1 (1.1)
Worries about RTD
 Emotional state of the patient following introduction of this topic 65 (71.4)
 Ethical and legal issues related to informed consent 6 (6.6)
 Ethical and legal issues related to the storage of human biological samples of deceased individuals 2 (2.2)
 That the technologies can easily be used for the wrong purposes 3 (3.3)
 Missing/Unknown/No response 15 (16.5)
Benefits about RTD
 Provides larger tumor samples 13 (14.3)
 Allows sampling of multiple tumor sites (heterogeneity) 23 (25.3)
 Allows testing on later stage or aggressive cancers (Stage III–IV) 10 (11.0)
 Ability to reveal or confirm newer therapies/methods 23 (25.3)
 Obtaining fresh tissue 15 (16.5)
 Missing/Unknown/No response 7 (7.7)